作者
Jincheng Huang,Jinjie Xia,Binxue Hong,Can Zhang,Li Zhao,Ping Yuan,Shan Jiang
摘要
OBJECTIVE: This study aims to evaluate the risk factors and prevalence of latent tuberculosis infection (LTBI) in patients with rheumatic diseases. METHODS: Databases including PubMed, EMBASE, Web of Science, Cochrane Library, CNKI, Vip, and Wanfang were searched. Data extraction was performed independently by two authors. The Newcastle-Ottawa Scale (NOS) was utilized to assess study quality. Heterogeneity was evaluated using I2 statistics and the chi-square test. The relative risk (RR), odds ratio (OR) with 95% confidence intervals (95% CI), and prevalence rate were calculated. Sensitivity analysis was conducted using the leave-one-out method. Publication bias was assessed using either the Begg rank correlation or Egger’s linear regression. RESULTS: Eighteen studies (13 cross-sectional and 5 cohort studies) involving 12,167 rheumatic patients were included. Increased risk of LTBI was associated with current smoking (OR = 1.50, 95%CI: 1.28–1.78), Golimumab treatment (OR = 2.90, 95% CI: 1.08–7.78), Chloroquine treatment ( OR = 1.27, 95% CI:1.01–1.61), age > 40 (OR = 1.84, 95% CI: 1.51–2.24) and a history of tuberculosis (TB) ( OR = 3.26, 95% CI: 1.87–5.68). Additionally, male rheumatic patients had a higher risk of LTBI compared to females (OR = 1.72, 95% CI: 1.46– 2.02). However, no significant associations were found between LTBI risk and history of smoking, duration of disease, history of Bacillus Calmette-Guérin, positive rheumatoid factor, corticosteroid use, diabetes history, TB exposure, Adalimumab or Etanercept use. The pooled prevalence rate of LTBI in rheumatic patients was 22% (95% CI: 18–27%). CONCLUSIONS: Current smoking, Golimumab treatment, Chloroquine treatment, age >40 and a history of TB are identified as risk factors for LTBI in rheumatic patients. Male patients are more prone to developing LTBI. The overall LTBI prevalence in rheumatic patients is high.